Healthcare & Life Sciences·Америка·2023
Ведущая глобальная биофармацевтическая компания
0%
Быстрее к пику выручки
$0B
Сохранённая выручка
0mo
Опережение плана запуска
Back to Our Work
Задача
На фоне истечения патентов двух блокбастеров требовалось ускорить запуск онкопрепаратов нового поколения и удержать выручку зрелых брендов в 30 странах.
Подход
We redesigned the go-to-market model around omnichannel engagement, deploying AI-driven physician targeting and next-best-action engines. We restructured the commercial organization from geography-based to therapeutic-area-aligned teams and built a launch excellence playbook that reduced time-to-peak-revenue by 40%.
Эффект
The first new therapy launched reached peak-year revenue projections 18 months ahead of plan. Legacy brand managed decline was slowed by 25%, preserving $1.2 billion in cumulative revenue over three years.